The US FDA (Food and Drug Administration) is warning telehealth companies against misleadingly promoting compound GLP-1 weight loss drugs.[1][3] The FDA has sent dozens of warning letters to companies that claim their compounded products are the same as FDA-approved drugs or that they contain the same active drug.[1][3] These firms, including Hims & Hers and other pharmacies, built large businesses over the years by offering compounded versions of popular GLP-1 drugs when branded versions were unavailable.[1] The FDA emphasizes that it cannot verify the quality, safety, and efficacy of unapproved compounded drugs.[3] Companies may not claim that unapproved compounded products are generic versions or that they are clinically proven to treat patients.[3] The FDA plans to use all available enforcement tools, including seizure of drugs and injunctions.[3]